The Food and Drug Administration has proposed revoking the regulation that authorizes the use of brominated vegetable oil (BVO) in food because the agency no longer considers it safe. Public comments on the proposed rule are due Jan. 17, 2024. Read on to learn what California and New York are doing related to BVO and which other ingredients the FDA is reviewing.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Allyson Maur Allyson Maur

Allyson advises on regulatory issues affecting diagnostics developers, biopharma manufacturers, and clinical laboratories, including CLIA/CLEP and FDA regulatory advice, MLR and MRC review of marketing and promotional materials, clinical studies, global data privacy issues, ethics & compliance, commercial contracting, commercial litigation and more.

Allyson advises on regulatory issues affecting diagnostics developers, biopharma manufacturers, and clinical laboratories, including CLIA/CLEP and FDA regulatory advice, MLR and MRC review of marketing and promotional materials, clinical studies, global data privacy issues, ethics & compliance, commercial contracting, commercial litigation and more.

Photo of Trent Taylor Trent Taylor

Trent is co-chair of the firm’s Consumer Products & Retail industry team. He focuses on defending complex class actions with an emphasis on product class actions, public and private nuisance litigation, environmental contamination suits, and food, cosmetic, and supplement labeling (including CBD) and…

Trent is co-chair of the firm’s Consumer Products & Retail industry team. He focuses on defending complex class actions with an emphasis on product class actions, public and private nuisance litigation, environmental contamination suits, and food, cosmetic, and supplement labeling (including CBD) and safety issues.

Photo of Royce DuBiner Royce DuBiner

Royce practices food and drug law with a focus on advising pharmaceutical, medical device, cannabis, dietary supplement, tobacco, food and beverage companies as well as investment firms on a range of regulatory matters. He is presently the lead of the Cannabis, Hemp, and…

Royce practices food and drug law with a focus on advising pharmaceutical, medical device, cannabis, dietary supplement, tobacco, food and beverage companies as well as investment firms on a range of regulatory matters. He is presently the lead of the Cannabis, Hemp, and CBD industry team.

Photo of Micaela Enger Micaela Enger

Micaela focuses her practice on corporate healthcare transactional matters and regulatory compliance.

Photo of Renee C. Kumon Renee C. Kumon

Renee practices within the firm’s Healthcare Department where she helps clients on healthcare regulatory, transactional, compliance, and corporate matters.